NCL collaborates with academia, industry and government laboratories to provide characterization of nano-enabled technologies. We leverage our expertise in physicochemical characterization, pharmacology, toxicology, immunology, and cancer biology to assist researchers in development efforts to expedite clinical translation of nanomedicines. Cancer nanomedicines are eligible to apply for free preclinical characterization services funded by the National Cancer Institute. NCL can also assist with specialized research and development projects in other areas of nanotechnology, including nanotech drug formulation, characterization of non-oncology nanomaterials, and more.
COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus